Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer extricates itself from investor suit with $400M settlement

Pfizer got a federal judge to toss an investor lawsuit last year tied its now-withdrawn pain drug Bextra. But it wasn't the only investor suit raising similar issues, namely that the board had not been forthright about issues with the drugs. Another was just days away from trial, that is until the drugmaker agreed to settle it for $400 million.

Pfizer's hunting for safe M&A bets, not high-risk pipeline deals

Pfizer, a deal-minded drugmaker sitting on billions in cash, is more interested in acquiring near-market assets than investing in long-term projects, counting on a blockbuster oncology collaboration to keep its early-stage pipeline afloat.

Novartis, Pfizer and Bristol-Myers hit the gas on R&D last year

Three of the world's largest drugmakers dialed up their R&D budgets in 2014, as Novartis, Pfizer and Bristol-Myers Squibb spent big on costly late-stage programs with hopes of delivering blockbuster new treatments in the coming year.

With generic losses on the horizon, Pfizer puts up a stormy 2015 forecast

Pfizer is forecasting 2015 earnings that ring in below the Street's expectations. But there could be some light at the end of the tunnel for Pfizer, as it posted promising performances for its cancer drugs and vaccine franchise.

Pfizer has $33B and the M&A world at its feet

Pfizer, which spent much of last year trying to acquire U.K. giant AstraZeneca, is now sitting on about $33 billion in cash, and the company's deal pedigree has analysts dreaming of major M&A down the line.

Deal-hungry Pfizer reportedly made a (failed) run at Teva. Who's next?

Two burning questions about Pfizer since the company backed off its ill-fated offer for AstraZeneca last May: Will the U.S.-based drug giant make another swoop at AstraZeneca? If not, who will Pfizer try to buy?

Pfizer wins recommendation for Prevenar expansion in Europe

The European Medicines Agency accepted Pfizer's application to expand its label for blockbuster vaccine Prevenar 13 back in August, and so far, an advisory committee likes what it sees.

MSF urges GSK, Pfizer to slash pneumococcal vaccine prices

The cost of vaccinating a child in the world's poorest countries is much higher than it was in 2001--68 times higher, according to Medecins Sans Frontieres. The international charity has a problem with that, and it's asking pneumococcal disease vaccine makers Pfizer and GlaxoSmithKline to fix it.

23andMe inks Pfizer deal, eyes 2015 resolution of FDA dispute

Days after unveiling a $60 million deal with Genentech, personal genomics pioneer 23andMe struck a new database-driven collaboration with Pfizer. There is even talk of a possible resolution with the FDA in 2015.

Playing catch-up, Pfizer looks to leapfrog Big Pharma's immuno-oncology line

Pfizer is well behind its rival titans in the race to cash in on a new class of cancer treatments. But instead of playing catch-up in skin cancer, the industry first immuno-oncology target, the drugmaker is skipping ahead to the next wave of malignancies.